Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) shot up 3.9% on Thursday . The company traded as high as $0.90 and last traded at $0.84. 15,371 shares were traded during trading, a decline of 22% from the average session volume of 19,680 shares. The stock had previously closed at $0.8081.
Matinas Biopharma Price Performance
The firm has a market capitalization of $5.29 million, a P/E ratio of -0.24 and a beta of 1.45. The stock’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $1.28.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.
Matinas Biopharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Read More
- Five stocks we like better than Matinas Biopharma
- Insider Selling Explained: Can it Inform Your Investing Choices?
- MP Materials Stock Soared After Earnings—Here’s the Real Reason
- Using the MarketBeat Dividend Tax Calculator
- Why Palantir Slide May Be a Setup for a Long-Term Opportunity
- How to Use the MarketBeat Excel Dividend Calculator
- Attention Income Investors: This REIT Is on Sale
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
